Underwriting AgreementUnderwriting Agreement • February 20th, 2018 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock, in each case other than (A) the Securities to be sold by the undersigned pursuant to the Underwriting Agreement, if any, and (B) transfers of shares of Common Stock:
INDEMNIFICATION AGREEMENTIndemnification Agreement • June 19th, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 2017 between Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [INDEMNITEE NAME] (“Indemnitee”).
DOVA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OFPreferred Stock Warrant Agreement • July 27th, 2018 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between DOVA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
AS WARRANT AGENTCommon Stock Warrant Agreement • July 27th, 2018 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between DOVA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
DOVA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFDebt Securities Warrant Agreement • July 27th, 2018 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [·], between DOVA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
Dova Pharmaceuticals, Inc. Common Stock ($0.001 par value per share) AT-THE- MARKET EQUITY OFFERING SALES AGREEMENTAt-the-Market Equity Offering Sales Agreement • July 27th, 2018 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • March 5th, 2019 • Dova Pharmaceuticals Inc. • Pharmaceutical preparations • North Carolina
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective December 17, 2018 (the “Effective Date”), which shall be Employee’s commencement of employment, by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and David S. Zaccardelli (the “Employee”).
AGREEMENT AND PLAN OF MERGER by and among: DOVA PHARMACEUTICALS, INC., SWEDISH ORPHAN BIOVITRUM AB (PUBL) and DRAGONFLY ACQUISITION CORP. September 30, 2019Merger Agreement • October 3rd, 2019 • Dova Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of September 30, 2019 (the “Agreement Date”), by and among: Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”); Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned Subsidiary of Parent (“Purchaser”); and Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement shall have the meanings ascribed to such terms in Section 1.
SERVICES AGREEMENTServices Agreement • June 2nd, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS SERVICES AGREEMENT (this “Agreement”) is entered into as of the 1st day of April, 2016, by and between PBM Capital Group, LLC, a Delaware limited liability company (“PBM”), and Dova Pharmaceuticals, LLC (the “Company”).
YM477 LICENSE AGREEMENTLicense Agreement • June 2nd, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Agreement is made as of August 15, 2005, by and between Astellas Pharma Inc., a company organized and existing under the laws of Japan and having its principal office at 3·11, Nihonbasbi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“Licensor”) and AkaRx Corp., a company organized and existing under the laws of Delaware and having its principal office at Mack Centre IV, 4th Floor, 61 S. Paramus Road, Paramus, NJ 07652 (“Licensee”).
SECURITY AGREEMENTSecurity Agreement • June 2nd, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Security Agreement (“Security Agreement”) is made as of March 30, 2016, by and between AkaRx, Inc., a Delaware corporation (“Debtor”), and Eisai Inc., a Delaware corporation (“Secured Party”). Debtor and Secured Party are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
STOCK PURCHASE AGREEMENT BETWEEN EISAI INC. and PBM AKX HOLDINGS, LLC Dated as of March 29, 2016Stock Purchase Agreement • June 2nd, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
STOCK PURCHASE AGREEMENT, dated as of March 29, 2016 (this “Agreement”), between Eisai Inc., a Delaware corporation (“Seller”), and PBM AKX Holdings, LLC, a Delaware limited liability company (“Purchaser”). Seller and Purchaser are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
GUARANTEEGuarantee • June 2nd, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Guarantee is made by PBM Capital Investments, LLC, a Delaware limited liability company (“Guarantor”), in favor of Eisai Inc., a Delaware corporation (“Seller”), as of March 30, 2016 (this “Guarantee”). Guarantor and Seller are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
TRANSITION SERVICES AGREEMENT by and between Eisai Inc. and AkaRx, Inc. Dated as of March 30, 2016Transition Services Agreement • June 2nd, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Transition Services Agreement (this “Agreement”) dated as of March 30, 2016 (the “Effective Date”), by and between Eisai Inc. a Delaware corporation (“Seller”), and AkaRx, Inc., a Delaware corporation (the “Company”). Seller and the Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT TO SERVICES AGREEMENTServices Agreement • May 9th, 2018 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to Services Agreement (this “Amendment”), dated as of March 29, 2018, is made by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and PBM Capital Group, LLC, a Delaware limited liability company (“PBM”). Capitalized terms used but not otherwise defined herein shall have the meanings given thereto in the Agreement (defined below).
AMENDED AND RESTATED TRANSITION SERVICES AGREEMENTTransition Services Agreement • November 8th, 2018 • Dova Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
EMPLOYMENT AGREEMENTEmployment Agreement • March 5th, 2019 • Dova Pharmaceuticals Inc. • Pharmaceutical preparations • North Carolina
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective December 17, 2018 (the “Effective Date”), which shall be Employee’s commencement of employment, by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Jason Hoitt (the “Employee”).
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 7th, 2019 • Dova Pharmaceuticals Inc. • Pharmaceutical preparations
THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of May 6, 2019 (the “Effective Date”), among (a) SILICON VALLEY BANK, a California corporation, in its capacity as administrative agent and collateral agent (“Agent”), (b) SILICON VALLEY BANK, a California corporation, as a lender (“SVB”), (c) WESTRIVER INNOVATION LENDING FUND VIII, L.P., a Delaware limited partnership (“WestRiver”), as a lender (SVB and WestRiver and each of the other “Lenders” from time to time a party hereto are referred to herein collectively as the “Lenders” and each individually as a “Lender”), and (d) (i) DOVA PHARMACEUTICALS, INC., a Delaware corporation (“Dova”), and (ii) AKARX, INC., a Delaware corporation (“AkaRx”) (Dova and AkaRx are hereinafter jointly and severally, individually and collectively, “Borrower”), provides the terms on which Agent and the Lenders shall lend to Borrower, and Borrower shall repay Agent and the Lenders. The parties agree as follows:
INVESTORS’ RIGHTS AGREEMENTInvestors' Rights Agreement • June 2nd, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day of September, 2016, by and among Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 5.9 hereof.
FIRST AMENDMENT TO OFFICE LEASE AGREEMENTOffice Lease Agreement • August 6th, 2019 • Dova Pharmaceuticals Inc. • Pharmaceutical preparations • North Carolina
THIS FIRST AMENDMENT TO OFFICE LEASE AGREEMENT (this “First Amendment”) is made this 13th day of May, 2019 (the “Effective Date”), by and between PINE FOREST 240 TT, LLC, a Delaware limited liability company (“Landlord”), and DOVA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
SUPPLY AGREEMENTSupply Agreement • June 9th, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
SUPPLY AGREEMENT (this “Agreement”) is made and entered into effective as of June 9, 2017 (the “Effective Date”) by and between Eisai Inc., a Delaware corporation (“Seller”), and AkaRx, Inc., a Delaware corporation (“Purchaser”). Seller and Purchaser are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SUBLEASE AGREEMENTSublease Agreement • June 19th, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS SUBLEASE (the “Sublease”) is made effective this 9th day of June, 2017 by and between Paidion Research, Inc. a North Carolina corporation (“Sublessor”) and Dova Pharmaceuticals, Inc., a Delaware corporation (“Sublessee”);
FIRST AMENDMENT TO THE CO-PROMOTION AGREEMENT by and betweenCo-Promotion Agreement • June 27th, 2019 • Dova Pharmaceuticals Inc. • Pharmaceutical preparations
This First Amendment (this “Amendment”) to the Co-Promotion Agreement is entered into on June 27, 2019 and effective as of July 1, 2019 (the “Amendment Effective Date”) by and between Dova Pharmaceuticals, Inc., a Delaware corporation (“Dova”), and Bausch Health US, LLC, formerly known as Valeant Pharmaceuticals North America LLC, a Delaware limited liability company (collectively, “Valeant”). Dova and Valeant are each referred to individually as a “Party” and together as the “Parties”.
OFFICE LEASE AGREEMENT BY AND BETWEEN PINE FOREST 240 TT, LLC (AS LANDLORD) AND DOVA PHARMACEUTICALS, INC. (AS TENANT) Durham, North Carolina 27517Office Lease Agreement • May 24th, 2018 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
THIS LEASE AGREEMENT (the “Lease”) is made and entered into as of the day of , 2018 (the “Effective Date”), by and between PINE FOREST 240 TT, LLC, a Delaware limited liability company (“Landlord”), and DOVA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO COMMERCIAL OUTSOURCING MASTER SERVICES AGREEMENT INTERIM DIRECT MODELCommercial Outsourcing Master Services Agreement • August 9th, 2018 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This First Amendment to the Commercial Outsourcing Master Services Agreement (this “Amendment”) is between Dova Pharmaceuticals, Inc. (the “Company”) and Integrated Commercialization Solutions, LLC (“ICS”). This Amendment is effective as of March 1, 2018 (the “Amendment Effective Date”).
FIRST AMENDMENT TO SUBLEASE AGREEMENTSublease Agreement • November 9th, 2017 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO SUBLEASE AGREEMENT (the “Amendment”) is made effective this 22nd day of September 2017 by and between Paidion Research, Inc. a North Carolina corporation (“Sublessor”) and Dova Pharmaceuticals, Inc., a Delaware corporation (“Sublessee”);
EMPLOYMENT AGREEMENTEmployment Agreement • January 31st, 2018 • Dova Pharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective January 31, 2018 (the “Effective Date”), by and between Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Mark W. Hahn (the “Employee”).
